Immunotherapy in head and neck cancer: The great challenge of patient selection.
Biomarkers
Head and neck cancer
Head and neck squamous cell carcinoma (HNSCC)
Immune checkpoint inhibitor (ICI)
Immunotherapy
Patient selection
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
04
09
2019
revised:
24
10
2019
accepted:
25
10
2019
pubmed:
19
11
2019
medline:
8
2
2020
entrez:
19
11
2019
Statut:
ppublish
Résumé
The development of immune checkpoint inhibitors (ICIs) revolutionized the therapeutic landscape in head and neck cancer. However, the majority of patients present primary resistance to ICIs and do not benefit from use of these agents, highlighting the need of developing predictive biomarkers to better determine who will benefit from treatment with ICIs. Patient's related clinical characteristics, disease related features, pathological and molecular factors, as well as emerging immune predictive biomarkers can be considered for the selection of those patients who would be the best candidate for immunotherapy. We examined these factors, emerging from the results of currently available studies in head and neck squamous cell carcinoma (HNSCC), in order to provide a useful tool which could assist the oncologist in their clinical practice.
Identifiants
pubmed: 31739116
pii: S1040-8428(19)30199-4
doi: 10.1016/j.critrevonc.2019.102829
pii:
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102829Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.